CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma

Published:2012-11 Issue:11 Volume:36 Page:1422-1427
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Sanchez Eric,Li Mingjie,Li Jennifer,Wang Cathy,Chen Haiming,Jones-Bolin Susan,Hunter Kathryn,Ruggeri Bruce,Berenson James R.

Funder

Teva Pharmaceuticals Inc

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference49 articles.

1. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy;Hideshima;Blood,2000

2. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma;Davies;Blood,2001

3. Thalidomide with dexamethasone for resistant multiple myeloma;Weber;Blood,2000

4. Combination therapy with thalidomide plus dexamethasone for newly diagnosed multiple myeloma;Rajkumar;J Clin Oncol,2002

5. Immunomodulatory drug CC5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma;Richardson;Blood,2002

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteasome inhibitors as anticancer agents;Expert Opinion on Therapeutic Patents;2023-10-30

2. Structural Aspects of Organic Compounds as Proteasome Inhibitors Addressed to Several Diseases;Research Topics in Bioactivity, Environment and Energy;2022

3. Delanzomib, a Novel Proteasome Inhibitor, Combined With Adalimumab Drastically Ameliorates Collagen-Induced Arthritis in Rats by Improving and Prolonging the Anti-TNF-α Effect of Adalimumab;Frontiers in Pharmacology;2021-11-22

4. Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions;Pharmaceutics;2021-02-28

5. The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges;Pharmacology & Therapeutics;2020-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3